Pancreatic Development Antibody Sampler Kit #85653
Product Information
Kit Usage Information
Protocols
- 5679: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, Immunofluorescence
- 7074: Western Blotting
- 30919: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence, Immunofluorescence
- 54551: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence, Flow
- 60433: Western Blotting, Immunoprecipitation (Agarose), Immunohistochemistry (Paraffin), Immunofluorescence
- 62953: Western Blotting, Immunoprecipitation (Magnetic), Immunofluorescence, Immunofluorescence
- 79737: Western Blotting, Immunoprecipitation (Agarose), Immunofluorescence, Immunofluorescence, ChIP Magnetic
Product Description
Background
The homeodomain protein NKX6.1 is a transcription factor that regulates pancreatic β-cell development (2). Overexpressed NKX6.1 stimulates rat pancreatic β-cell proliferation and increases glucose-stimulated insulin secretion (GSIS) (8). The effect on GSIS was shown to be mediated by the upregulation of prohormone VGF expression and the subsequent potentiation by TLQP-21, a peptide derived from VGF (9). Both nuclear receptors Nr4a1 and Nr4a3 are essential for pancreatic β-cell proliferation driven by overexpressed NKX6.1 (10). In addition, studies suggest that NKX6.1 is a suppressor for epithelial-mesenchymal transition (EMT), leading to inhibition of tumor metastasis (11).
Paired box (PAX) proteins are a family of transcription factors that play important and diverse roles in animal development (12). Nine PAX proteins (PAX1-9) have been described in humans and other mammals. They are defined by the presence of an amino-terminal "paired" domain, consisting of two helix-turn-helix motifs, with DNA binding activity (13). PAX proteins are classified into four structurally distinct subgroups (I-IV) based on the absence or presence of a carboxy-terminal homeodomain and a central octapeptide region (13). PAX proteins play critically important roles in development by regulating transcriptional networks responsible for embryonic patterning and organogenesis (14); a subset of PAX proteins also maintains functional importance during postnatal development (15). Research studies have implicated genetic mutations that result in aberrant expression of PAX genes in a number of cancer subtypes (12-14), with members of subgroups II and III identified as potential mediators of tumor progression (13).
Neurogenic differentiation factor 1 (NeuroD1) is a member of the basic helix-loop-helix (bHLH) family of transcription factors. These proteins function by forming heterodimers with E-proteins and binding to the canonical E-box sequence CANNTG (16,17). NeuroD1 is crucially important in both the pancreas and the developing nervous system and plays a large role in the development of the inner ear and mammalian retina (18). Mice lacking NeuroD1 become severely diabetic and die shortly after birth due to defects in β-cell differentiation (17-20).
MAFA and MAFB belong to the musculoaponeurotic fibrosarcoma (MAF) family of basic leucine-zipper transcription factors (21). In the mouse embryo, MAFA expression is first detected at E13.5, restricted to Nkx6.1-positive insulin-producing islet cells (22). Expression of the MAFA gene is sensitive to physiological glucose levels, and genomic targets regulated by MAFA include β-cell transcription factors (e.g., PDX1) and the insulin gene (22,23). In mouse embryo, MAFB expression is first detected at E10.5 (24,25). Early in development, MAFB drives differentiation of both glucagon-producing α-cells and insulin-producing β-cells in the pancreas, but later plays a more decisive role in the maturation and maintenance of functional α-cells (26,27).
- Kaneto, H. et al. (2008) Endocr J 55, 235-52.
- Habener, J.F. et al. (2005) Endocrinology 146, 1025-34.
- Guz, Y. et al. (1995) Development 121, 11-8.
- Ohlsson, H. et al. (1993) EMBO J 12, 4251-9.
- Watada, H. et al. (1996) Diabetes 45, 1826-31.
- Waeber, G. et al. (1996) Mol Endocrinol 10, 1327-34.
- Cockburn, B.N. et al. (2004) J Clin Endocrinol Metab 89, 971-8.
- Schisler, J.C. et al. (2008) Mol Cell Biol 28, 3465-76.
- Stephens, S.B. et al. (2012) Cell Metab 16, 33-43.
- Tessem, J.S. et al. (2014) Proc Natl Acad Sci USA 111, 5242-7.
- Li, H.J. et al. (2016) Oncogene 35, 2266-78.
- Lang, D. et al. (2007) Biochem Pharmacol 73, 1-14.
- Robson, E.J. et al. (2006) Nat Rev Cancer 6, 52-62.
- Wang, Q. et al. (2008) J Cell Mol Med 12, 2281-94.
- Blake, J.A. et al. (2008) Dev Dyn 237, 2791-803.
- Schonhoff, S.E. et al. (2004) Endocrinology 145, 2639-44.
- Sharma, A. et al. (1999) Mol Cell Biol 19, 704-13.
- Chae, J.H. et al. (2004) Mol Cells 18, 271-88.
- Miyata, T. et al. (1999) Genes Dev 13, 1647-52.
- Naya, F.J. et al. (1997) Genes Dev 11, 2323-34.
- Hang, Y. and Stein, R. (2011) Trends Endocrinol Metab 22, 364-73.
- Matsuoka, T.A. et al. (2004) Proc Natl Acad Sci USA 101, 2930-3.
- Vanhoose, A.M. et al. (2008) J Biol Chem 283, 22612-9.
- Nishimura, W. et al. (2006) Dev Biol 293, 526-39.
- Artner, I. et al. (2006) Diabetes 55, 297-304.
- Katoh, M.C. et al. (2018) Mol Cell Biol 38, e00504-17. doi: 10.1128/MCB.00504-17.
- Artner, I. et al. (2007) Proc Natl Acad Sci USA 104, 3853-8.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.